Good points Jeff however atl 1103 normalized igf-1 in one patient once the dosing is fine tuned there will be no reason majority of patients can't expect the same results with the correct dose. Somervert alone can't do that. That would justify the price of alt 1103 combined with Somervert
A patent of the combined drugs Will not expire until 2032.
dyor.
ANP & Biogen Indec, page-65
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $80.86M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 377000 | 8.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 94250 | 1 |
View Market Depth
| Last trade - 09.26am 05/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |
Day chart unavailable